Log In
Print
BCIQ
Print
Print this Print this
 

Elidel, pimecrolimus

Also known as: ASM 981

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionNon-steroidal pimecrolimus (ascomycin derivative) 1% cream
Molecular Target FK506 binding protein (macrophilin-12)
Mechanism of ActionCalcineurin inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDermatitis
Indication DetailsModerate atopic eczema; Treat atopic dermatitis (eczema); Treat mild to moderate atopic dermatitis (eczema)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$420.0M

$420.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today